{
    "clinical_study": {
        "@rank": "36898", 
        "arm_group": {
            "arm_group_label": "MS3TMRI / TRUS Guided Biopsy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive\n      prostate cancer compared to men in the general population.\n\n      Stand of care screening for men with a BRCA mutation includes PSA testing and digital rectal\n      examination (DRE), the same as with men in the general population.\n\n      This study is being done to assess whether there is value in using MRI as a screening tool\n      to detect prostate cancer at an earlier stage than may otherwise be detected using standard\n      of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in\n      this specific population at high risk for aggressive disease."
        }, 
        "brief_title": "Prostate Screening Study Using MRI in BRCA Carriers", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "To determine the value of using Multispectral 3T MRI (MS3TMRI) for prostate cancer screening\n      in men with a high risk of developing early onset aggressive prostate cancer given known\n      BRCA1 or BRCA2 mutation carrier status, with no prior prostate cancer diagnosis, independent\n      of baseline PSA levels.\n\n        -  Determine the prevalence of prostate cancer in BRCA1 and BRCA2 mutation carriers\n           independent of baseline PSA levels.\n\n        -  To evaluate the accuracy of tumor targeting based on MRI and ultrasound (US) tumor\n           co-localization. To evaluate the sensitivity, specificity, PPV, NPV, and accuracy of an\n           automated computer aided diagnosis method (CAD) applied to MS3TMRI in the prediction of\n           zonal biopsy results for the presence or absence of a significant cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Enrolled in the Male Hereditary Cancer Research Program at Sunnybrook Health Sciences\n             Center.\n\n          -  Have positive genetic testing for a pathogenic BRCA1 or BRCA2 mutation.\n\n          -  Clinically eligible for and willing to undergo ultrasound biopsy within 4 weeks after\n             the MRI.\n\n          -  Be 50 years of age or older.\n\n        Exclusion Criteria:\n\n          -  Claustrophobia\n\n          -  Contraindication to MRI\n\n          -  Contraindication to receiving low molecular weight MRI contrast agent\n\n          -  Previously diagnosed with prostate cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990521", 
            "org_study_id": "500-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "MS3TMRI / TRUS Guided Biopsy", 
                "description": "Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).", 
                "intervention_name": "MS3TMRI / TRUS Guided Biopsy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "MS3TMRI / TRUS Guided Biopsy", 
                "description": "Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.\nA recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished).", 
                "intervention_name": "MS3TMRI / TRUS Guided Biopsy", 
                "intervention_type": "Device", 
                "other_name": [
                    "Multispectral 3T MRI", 
                    "Transrectal Ultrasound"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "danny.vesprini@sunnybrook.ca", 
                "last_name": "Danny J Vesprini, MD, FRCPC", 
                "phone": "416-480-4806"
            }, 
            "contact_backup": {
                "email": "justin.lorentz@sunnybrook.ca", 
                "last_name": "Justin A Lorentz, MSc", 
                "phone": "416-480-5000", 
                "phone_ext": "83683"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M4N 3M5"
                }, 
                "name": "Sunnybrook Odette Cancer Centre"
            }, 
            "investigator": [
                {
                    "last_name": "Justin A Lorentz, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Danny J Vesprini, MD, FRCPC", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Screening Male BRCA Mutation Carriers: Effectiveness of Multispectral 3T Magnetic Resonance Imaging", 
        "overall_contact": {
            "email": "danny.vesprini@sunnybrook.ca", 
            "last_name": "Danny J Vesprini, MD MSc FRCPC", 
            "phone": "416-480-4806"
        }, 
        "overall_contact_backup": {
            "email": "justin.lorentz@sunnybrook.ca", 
            "last_name": "Justin A Lorentz, MSc", 
            "phone": "416-480-500", 
            "phone_ext": "83683"
        }, 
        "overall_official": {
            "affiliation": "Sunnybrook Health Sciences Centre", 
            "last_name": "Danny J Vesprini, MD MSc FRCPC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure of prostate MRI to determine the PPV of MRI for detection of actionable prostate cancer", 
            "measure": "Prostate MRI in BRCA carriers", 
            "safety_issue": "Yes", 
            "time_frame": "2 years (January 2016)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990521"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Toronto Sunnybrook Regional Cancer Centre", 
            "investigator_full_name": "Danny Vesprini, MD, MSc, FRCPC", 
            "investigator_title": "Radiation Oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Prevalence of any prostate cancer compared to actionable cancer in men with a BRCA1 or BRCA2 mutation independent of serum PSA value.", 
            "measure": "Prostate cancer in BRCA carriers", 
            "safety_issue": "Yes", 
            "time_frame": "2 years January 2016"
        }, 
        "source": "Toronto Sunnybrook Regional Cancer Centre", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Sunnybrook Health Sciences Centre", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Women's College Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Toronto Sunnybrook Regional Cancer Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}